Global Cancer Spit Test Device Market, By Product Type (Saliva Collection Kits, Fluid Specific Devices, Oral Swab, Bar-Code Labels, Saliva Cryostorage Box, Others), Site Of Collection (Sub-Mandibular/Sub-Lingual Gland, Parotid Gland, Minor Salivary Gland), Application (Liver-Lung Cancer, Breast Cancer, Colon And Rectal Cancer, Prostate Cancer, Pancreatic Cancer, Oral Cancer, Thyroid Cancer, Endometrial Cancer, Kidney Cancer, Leukemia, Melanoma, Non-Hodgkin Lymphoma, Others), Age Group (Adult, Pediatric), Method of Collection (Passive Drool, Oral Swab, Others), End User (Hospitals, Diagnostic Laboratories, Oncology Speciality Clinics, Cancer Research Institutes, Others), Distribution Channel (Direct Tenders, Retail Sales, Others) – Industry Trends and Forecast to 2031.
Cancer Spit Test Device Market Analysis and Size
The cancer spit test device market is witnessing significant growth driven by the increasing prevalence of dental caries and a growing emphasis on preventive dentistry. SDF, a minimally invasive treatment, has gained popularity for arresting dental caries and preventing their progression. The rising awareness of oral health, especially in pediatric dentistry, coupled with the ease of application and cost-effectiveness of SDF, contributes to its widespread adoption. In addition, the product's ability to address dental caries in challenging-to-treat populations, such as young children and individuals with special needs, further propels its market growth. As dental professionals increasingly recognize the benefits of SDF in managing caries, the market is poised for continued expansion in the coming years.
Data Bridge Market Research analyses that the global cancer spit test device market, which was USD 552.66 million in 2023, would rocket up to USD 1345.72 million by 2031 and is expected to undergo a CAGR of 9.7% during the forecast period. “Direct tenders" dominate the distribution channel segment of the cancer spit test device market due to increasing awareness of proper treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Saliva Collection Kits, Fluid Specific Devices, Oral Swab, Bar-Code Labels, Saliva Cryostorage Box, Others), Site Of Collection (Sub-Mandibular/Sub-Lingual Gland, Parotid Gland, Minor Salivary Gland), Application (Liver-Lung Cancer, Breast Cancer, Colon And Rectal Cancer, Prostate Cancer, Pancreatic Cancer, Oral Cancer, Thyroid Cancer, Endometrial Cancer, Kidney Cancer, Leukemia, Melanoma, Non-Hodgkin Lymphoma, Others), Age Group (Adult, Pediatric), Method of Collection (Passive Drool, Oral Swab, Others), End User (Hospitals, Diagnostic Laboratories, Oncology Speciality Clinics, Cancer Research Institutes, Others), Distribution Channel (Direct Tenders, Retail Sales, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East & Africa
|
|
Market Players Covered
|
DNA Genotek (Canada), Salimetrics, LLC (U.S.), PeriRx (U.S.), Color Health, Inc. (U.S.), SARSTEDT AG. Co. KG (Germany), Miraclean Technology Co., Ltd. (Taiwan), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN (Germany), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), BD (Becton, Dickinson and Company - U.S.), Biocartis (Belgium), bioMérieux SA (France), Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Oasis Diagnostics Corporation (U.S.), Canvax (Spain, a subsidiary of Dobuss)
|
|
Market Opportunities
|
|
Market Definition
"Cancer spit test device" refers to the diagnostic devices designed to detect cancer through the analysis of saliva samples. These non-invasive devices are aimed at identifying specific biomarkers, genetic mutations, or other indicators associated with various types of cancer. The use of saliva as a diagnostic medium provides a convenient and patient-friendly approach, eliminating the need for invasive procedures such as blood tests or tissue biopsies. These devices play a crucial role in early cancer detection, monitoring, and screening.
Cancer Spit Test Device Market Dynamics
Drivers
- Rising Cancer Cases
The increasing incidence of cancer worldwide is a major driver for the cancer spit test device market. These devices offer a non-invasive and convenient method for early cancer detection.
- Advancements in Diagnostic Technologies
Continuous advancements in diagnostic technologies, including the development of more sensitive and specific cancer biomarkers drive the adoption of cancer spit test devices.
- Growing Emphasis on Early Detection
The focus on early detection of cancer for better prognosis and treatment outcomes is propelling the demand for screening tools, with spit tests being a promising avenue.
Opportunities
- Rising Healthcare Awareness
Increasing awareness about the importance of regular health check-ups and cancer screening creates opportunities for the adoption of spit test devices.
- Technological Innovations
Ongoing technological innovations, such as the incorporation of artificial intelligence in data analysis, present opportunities for enhancing the performance and reliability of spit test devices.
Challenges/Restraints
- Accuracy and Sensitivity Concerns
One of the challenges is ensuring the accuracy and sensitivity of spit tests, as false positives or negatives can have significant consequences on patient outcomes and healthcare costs.
- Regulatory Approval Challenges
Obtaining regulatory approvals for cancer spit test devices involves stringent processes, and meeting the required standards can be a hurdle for market players.
Recent Development
- In February 2021, Thermo Fisher Scientific was recognized with Six CMO Leadership Awards. It won across all six categories including capabilities, compatibility, expertise, quality, reliability, and service. This is the second consecutive year Thermo Fisher has received this recognition across all six categories and the eighth time overall that the company has been honored by the CMO Leadership Awards. This has increased the credibility of the company and aided in revenue generation
- In January 2021, DNA Genotek announced that the U.S. Food and Drug Administration (FDA) has granted a general use 510(k) clearance for its OrageneDx family of products. This FDA approval has increased the credibility of the company in the market and increased the sales of this product
Global Cancer Spit Test Device Market Scope
The cancer spit test device market is segmented on the basis of product type, site of collection, application, age group, method of collection, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets
Product type
- Saliva Collection Kits
- Fluid Specific Devices
- Oral Swab
- Bar-Code Labels
- Saliva Cryostorage Box
- Others
Site of Collection
- Sub-Mandibular/Sub-Lingual Gland
- Parotid Gland
- Minor Salivary Gland
Application
- Liver-Lung Cancer
- Breast Cancer
- Colon And Rectal Cancer
- Prostate Cancer
- Pancreatic Cancer
- Oral Cancer
- Thyroid Cancer
- Endometrial Cancer
- Kidney Cancer
- Leukemia
- Melanoma
- Non-Hodgkin Lymphoma
- Others
Age Group
- Adult
- Pediatric
Method of Collection
- Passive Drool
- Oral Swab
- Others
End User
- Hospitals
- Diagnostic Laboratories
- Oncology Specialty Clinics
- Cancer Research Institutes
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Global Cancer Spit Test Device Market Regional Analysis/Insights
The cancer spit test device market is analyzed and market size insights and trends are provided by country, product type, site of collection, application, age group, method of collection, end user, and distribution channel.
The countries covered in the market report are U.S., Canada, Mexico, Brazil, Argentina, rest of South America, Germany, France, Italy, U.K., Belgium, Spain, Russia, Turkey, Netherlands, Switzerland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, U.A.E., Saudi Arabia, Egypt, South Africa, Israel, and rest of Middle East and Africa.
North America is expected to dominate the market due to increasing prevalence of chronic diseases in the region. In addition, the surging number of initiatives taken by the pharmaceutical organizations to generate novel formulation mainly for pediatric population and rising healthcare expenditure will further propel the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to surging government initiatives to spread awareness and increasing the geriatric population in this region. Also, the development of healthcare infrastructure will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The cancer spit test device market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cancer spit test device market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on cancer spit test device market. The data is available for historic period 2010-2020.
Competitive Landscape and Global Cancer Spit Test Device Market Share Analysis
The cancer spit test device market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cancer spit test device market.
Some of the major players operating in the cancer spit test device market are:
- DNA Genotek (Canada)
- Salimetrics, LLC (U.S.)
- PeriRx (U.S.)
- Color Health, Inc. (U.S.)
- SARSTEDT AG. Co. KG (Germany)
- Miraclean Technology Co., Ltd. (Taiwan)
- Agilent Technologies, Inc. (U.S.)
- Illumina, Inc. (U.S.)
- QIAGEN (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
- Abbott (U.S.)
- BD (Becton, Dickinson and Company - U.S.)
- Biocartis (Belgium)
- bioMérieux SA (France)
- Siemens Healthcare GmbH (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Oasis Diagnostics Corporation (U.S.)
- Canvax (Spain, a subsidiary of Dobuss)
SKU-